AU Patent

AU2023376438A1 — Vasopressin formulation

Assigned to Hikma Pharmaceuticals USA Inc · Expires 2025-06-05 · 1y expired

What this patent protects

The present disclosure relates to a ready-to-use formulation of vasopressin, the process for making such formulations and use of such formulations for treatment of a patient in need thereof.

USPTO Abstract

The present disclosure relates to a ready-to-use formulation of vasopressin, the process for making such formulations and use of such formulations for treatment of a patient in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023376438A1
Jurisdiction
AU
Classification
—
Expires
2025-06-05
Drug substance claim
No
Drug product claim
No
Assignee
Hikma Pharmaceuticals USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.